The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus
Open accessAbstract
BMS-200475 is a novel carbocyclic 2'-deoxyguanosine analog found to possess potent and selective anti-hepatitis B virus (anti-HBV) activity. BMS-200475 is distinguished from guanosine by replacement of the natural furanose oxygen on the sugar moiety with an exo carbon-carbon double bond. In the HepG2 stably transfected cell line 2.2.15, BMS-200475 had a 50% effective concentration (EC50) of 3.75 nM against HBV, as determined by analysis of secreted HBV DNA. Structurally related compounds with adenine, iodouracil, or thymine base substitutions were significantly less potent or were inactive. Direct comparison of the antiviral activities of BMS-200475 with those of a variety of other nucleoside analogs, including lamivudine (EC50 = 116.26 nM), demonstrated the clearly superior in vitro potency of BMS-200475 in 2.2.15 cells. Intracellular HBV replicative intermediates were uniformly reduced when cells were treated with BMS-200475, but rebounded after treatment was terminated. The concentration of BMS-200475 causing 50% cytotoxicity in 2.2.15 cell cultures was 30 microM, approximately 8,000-fold greater than the concentration required to inhibit HBV replication in the same cell line. Treatment with BMS-200475 resulted in no apparent inhibitory effects on mitochondrial DNA content.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Detection of specific sequences among DNA fragments separated by gel electrophoresis
Southern, E. M. (1975) · Journal of Molecular Biology · doi:10.1016/s0022-2836(75)80083-0 · Cited by 32,249
Sells, M. A., Chen, M. L., & Acs, G. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.4.1005 · Cited by 1,117
THE MOLECULAR BIOLOGY OF THE HEPATITIS B VIRUSES
Ganem, D., & Varmus, H. E. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.003251 · Cited by 1,084
Perrillo, R. P., Schiff, E. R., Davis, G. L., Bodenheimer, H. C., Lindsay, K., Payne, J., Dienstag, J. L., O'Brien, C., Tamburro, C., Jacobson, I. M., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199008023230503 · Cited by 840
A Preliminary Trial of Lamivudine for Chronic Hepatitis B Infection
Dienstag, J. L., Perrillo, R. P., Schiff, E. R., Bartholomew, M., Vicary, C., & Rubin, M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512213332501 · Cited by 800
Weislow, O. S., Kiser, R., Fine, D. L., Bader, J., Shoemaker, R. H., & Boyd, M. R. (1989) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/81.8.577 · Cited by 685
Tisdale, M., Kemp, S. D., Parry, N. R., & Larder, B. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.12.5653 · Cited by 603
Ling, R., Mutimer, D., Ahmed, M., Boxall, E. H., Elias, E., Dusheiko, G. M., & Harrison, T. J. (1996) · Hepatology · doi:10.1002/hep.510240339 · Cited by 466
Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis
Grellier, L., Mutimer, D., Ahmed, M., Brown, D. J., Burroughs, A. K., Rolles, K., McMaster, P., Beranek, P. A., Kennedy, F., Kibbler, H., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)04444-3 · Cited by 391
Boucher, C. A., Cammack, N., Schipper, P., Schuurman, R., Rouse, P., Wainberg, M. A., & Cameron, J. M. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.10.2231 · Cited by 313
Cited by
A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B
Chang, T.-T., Gish, R. G., de Man, R., Gadano, A., Sollano, J., Chao, Y.-C., Lok, A. S., Han, K.-H., Goodman, Z., Zhu, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051285 · Cited by 1,444
Self-citationEntecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B
Lai, C.-L., Shouval, D., Lok, A. S., Chang, T.-T., Cheinquer, H., Goodman, Z., DeHertogh, D., Wilber, R., Zink, R. C., Cross, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051287 · Cited by 1,188
Self-citationMechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir
Tchesnokov, E. P., Feng, J. Y., Porter, D. P., & Götte, M. (2019) · Viruses · doi:10.3390/v11040326 · Cited by 622
Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B
Sherman, M., Yurdaydin, C., Sollano, J., Silva, M., Liaw, Y., Cianciara, J., Boron–Kaczmarska, A., Martin, P., Goodman, Z., Colonno, R., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.04.007 · Cited by 413
Self-citationEntecavir Therapy for up to 96 Weeks in Patients With HBeAg-Positive Chronic Hepatitis B
Gish, R. G., Lok, A. S., Chang, T., de Man, R. A., Gadano, A., Sollano, J., Han, K., Chao, Y., Lee, S., Harris, M., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.08.025 · Cited by 367
Self-citation
Metadata
- Authors
- Innaimo, S. F., Seifer, M., Bisacchi, G. S., Standring, D. N., Zahler, R., & Colonno, R. J.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1997-07
- Volume
- 41
- Issue
- 7
- Pages
- 1444-1448
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2130575875
- Cited by
- 273
- References
- 16
- FWCI
- 9.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. https://app.cochat.ai/papers/10.1128/aac.41.7.1444
- The paper
- Innaimo, S. F., Seifer, M., Bisacchi, G. S., Standring, D. N., Zahler, R., & Colonno, R. J. (1997). Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.41.7.1444
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.